Meeting
2018 ASCO Annual Meeting
A phase II study of ramucirumab for advanced, pre-treated biliary cancers.
Authors
Jonathan Mizrahi
University of Texas MD Anderson Cancer Center, Houston, TX
Jonathan Mizrahi , Milind M. Javle , Lianchun Xiao , Gauri R. Varadhachary , Kanwal Pratap Singh Raghav , Robert A. Wolff , Rachna T. Shroff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02520141
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4081)
DOI
10.1200/JCO.2018.36.15_suppl.4081
Abstract #
4081
Poster Bd #
270
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial.
First Author: Ashwin Reddy Sama
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
First Author: Jia Fan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
First Author: Richard D. Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1.
First Author: Masayuki Furukawa